Introgen Therapeutics, Inc. Receives European Patent For Commercial Production Of Adenovirus; Claims Cover Production Of Commercial Scale Adenoviral Compositions
Published: Dec 13, 2006
AUSTIN, Texas, Dec. 13 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. announced today that it has been granted a broad patent by the European Patent Office ("EPO") that relates to the production of purified adenoviral compositions that are commercially scaleable and can be readily validated for regulatory purposes. The patent, number 0968284, is entitled "An Improved Method for the Production and Purification of Adenoviral Vectors." This patent complements three previously issued U.S. patents in Introgen's intellectual property portfolio related to the production of adenoviral vectors. Several products in Introgen's clinical program utilize adenoviral vectors and the processes covered under this newly issued patent were developed exclusively at Introgen.
David L. Parker, PhD, JD, Introgen's senior vice president of Intellectual Property commented, "This patent is the European complement to our existing United States adenovirus production/purification technology. It is of particular importance in that it covers the production of adenovirus of commercial scale quantity and purity, regardless of whether the adenovirus is used as a delivery system for therapeutic genes, used directly as a therapeutic agent, used as a vaccine or vaccine component or simply used for research and development purposes. The purification technology covered by this patent is currently being employed throughout the industry by Introgen and others, and is thus recognized as an industry standard for clinical production of adenovirus."
"We believe this key enabling technology validates Introgen's leadership in adenovirus production and purification technology," said Peter Clarke, PhD, Introgen's vice president of Production and Technical Processes. "This patent arises out of our extensive process development efforts at Introgen. The underlying technologies have been validated by our ability to supply high quality adenoviral vectors for our clinical development programs and by the selection of Introgen, under a process guided by the Food and Drug Administration, to manufacture the worldwide adenoviral reference material for use by companies and academic institutions developing adenovirus-based products.
Adenovirus has been used in hundreds of thousands of patients in government, industry and academia for vaccine and therapy programs. Adenoviruses can be genetically altered so that they are unable to replicate in humans and they do not mix with a patient's DNA. Adenoviruses have important properties that lend themselves readily to commercial scale manufacturing.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN clinical development program for treatment of cancer or other diseases and the intellectual property portfolio that includes methods for the production and purification of adenoviral vectors. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: email@example.comIntrogen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, Ext. 322, or firstname.lastname@example.org
Web site: http://www.introgen.com/